No Mortality Benefit Seen for Dialysis Drug (CME/CE)

(MedPage Today) -- The routine use of the calcimimetic agent cinacalcet (Sensipar) conferred little mortality benefit in patients with severe chronic kidney disease and is commonly associated with side effects, a meta-analysis confirmed.
Source: MedPage Today Nephrology - Category: Urology & Nephrology Source Type: news